DETOUR2 Evaluates PTAB With Endologix Detour System in Complex SFA Disease at 3 Years

July 8, 2026—Endologix LLC announced 36-month results from the DETOUR2 clinical trial evaluating percutaneous transmural arterial bypass (PTAB) using the company’s Detour system. The findings were published by Sean P. Lyden, MD, et al in JSCAI.

According to the company, DETOUR2 is a prospective, single-arm, international, multicenter clinical evaluation of the safety and effectiveness of PTAB using the Detour system in patients with long and complex femoropopliteal lesions. The study enrolled 202 patients across 32 clinical sites.

As reported in the Endologix press release, the results demonstrated sustained safety and durable clinical outcomes through 36 months, supporting PTAB with the Detour system as a minimally invasive alternative for patients with complex peripheral artery disease.

The study showed strong long-term outcomes in a highly complex superficial femoral artery (SFA) disease patient population with a mean lesion length of 32.7 cm, 96% chronic total occlusions, and 70% severely calcified lesions.

As outlined by Endologix, key results through 3 years included the following:

• Primary patency of 58.2%
• Patency defined as freedom from occlusion (flow/no flow) of 84%
• Freedom from clinically driven target lesion revascularization of 66.8%
• Freedom from major adverse limb events of 64.5%
• Freedom from major amputation of 97.9% (unchanged from 12 months)
• Symptomatic deep vein thrombosis of 4.1%, with no pulmonary emboli reported (unchanged from 12 months)

Additionally, clinical success, defined as improvement in Rutherford clinical classification, was achieved in 96.7% of patients at 36 months, reflecting sustained improvement in symptoms and functional status, noted the company.

“Long-segment femoropopliteal disease remains one of the most challenging areas in peripheral vascular intervention,” commented the study’s lead author Prakash Krishnan, MD, in the company’s press release. “The DETOUR2 results demonstrate that percutaneous bypass using the Detour system can deliver durable outcomes through 3 years with favorable safety, providing an important treatment option for patients with complex SFA disease.”